scholarly journals Efficacy and Tolerance of Single-dose Azithromycin for Treatment of Chlamydial Cervicitis During Pregnancy

1995 ◽  
Vol 3 (5) ◽  
pp. 189-192 ◽  
Author(s):  
Joseph M. Miller
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Oral Dose ◽  
Pregnant Women ◽  
Retrospective Review ◽  
Cure Rate ◽  
Dose Oral ◽  
Oral Azithromycin

Objective: The intent of this study was to determine the efficacy and tolerance of single-dose oral azithromycin in the treatment of pregnant women with endocervical chlamydial carriage.Methods: A retrospective review of clinic records over a two-year period identified pregnant patients treated with a single 1-g dose of azithromycin for chlamydial carriage. The side effects and subsequent chlamydial carriage (test of cure) were noted.Results: A total of 146 pregnant women treated with azithromycin was reviewed. A cure rate of 96% was found. Side effects were reported in 5%.Conclusions: A single 1-g oral dose of azithromycin is effective for the treatment of chlamydia and is well tolerated in pregnant women.

scholarly journals A Single Dose Oral Azithromycin versus Intramuscular Benzathine Penicillin for the Treatment of Yaws-A Randomized Non Inferiority Trial in Ghana

2017 ◽  
Vol 11 (1) ◽  
pp. e0005154 ◽  
Author(s):  
Cynthia Kwakye-Maclean ◽  
Nsiire Agana ◽  
John Gyapong ◽  
Priscilia Nortey ◽  
Yaw Adu-Sarkodie ◽  
...  
Keyword(s):  
Single Dose ◽  
Benzathine Penicillin ◽  
Dose Oral ◽  
Oral Azithromycin

scholarly journals Efficacy of a single oral dose artesunate plus sulfalene/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in Kenyan children: randomised, exploratory, open-label trial

2020 ◽  
Author(s):  
Erick M.O Muok ◽  
Vincent O. Were ◽  
Charles O. Obonyo
Keyword(s):  
Single Dose ◽  
Oral Dose ◽  
Single Oral Dose ◽  
Cure Rate ◽  
Open Label ◽  
Serious Adverse Event ◽  
Western Kenya ◽  
Potential Alternative ◽  
Periodic Administration ◽  
To Receive

Abstract Background: The global control strategy for schistosomiasis is the periodic administration of praziquantel. Schistosomes have developed reduced susceptibility to praziquantel. Artemisinin-based drug combinations are promising alternatives to praziquantel, but it is unclear whether a single dose of an artemisinin-based drug combination is as effective and safe as praziquantel. We assessed the efficacy and safety of a single oral dose of artesunate plus sulfalene/pyrimethamine in the treatment of schistosomiasis. Methods: An exploratory, open-label randomized trial, was carried out in Rarieda sub-County, western Kenya to compare the efficacy of a single oral dose of artesunate plus sulfalene/pyrimethamine (12mg/kg of artesunate) to a standard single dose of praziquantel (40mg/kg) in the treatment of school children (aged 6 to 15 years) with S. mansoni infection. The primary outcomes were cure and egg reduction rates on day 28 after treatment in the per-protocol population.Results: A total of 73 S. mansoni infected children were included and randomized to receive either artesunate plus sulfalene/pyrimethamine (n=39) or praziquantel (n=34). 67 children completed the study. The cure rate was 69.4% (25/36) in the artesunate plus sulfalene/pyrimethamine group and 80.6% (25/31) in the praziquantel group (p=0.294). Egg reduction rates were 96.2% in the artesunate plus sulfalene/pyrimethamine group and 82.9% in the praziquantel group (p=0.339). Ten children treated with praziquantel developed adverse events compared with four in the artesunate plus sulfalene/pyrimethamine group. There was no serious adverse event. Conclusion: A single oral dose of artesunate plus sulfalene/pyrimethamine was safe and as efficacious as praziquantel in the treatment of S. mansoni in Kenyan children. These results should be confirmed in larger randomized controlled trials. Combination treatment with praziquantel plus artemisinin-based combination therapies may be a potential alternative for improving praziquantel efficacy and transmission control. Trial Registration: ClinicalTrials.gov, number NCT01054651.

The Treatment of Non-Gonococcal Urethritis with Single Dose Oral Azithromycin

1995 ◽  
Vol 23 (5) ◽  
pp. 386-393 ◽  
Author(s):  
T Erdog#x0342;ru ◽  
A Ag#x0342;açfidan ◽  
M Önel ◽  
S Badur ◽  
Ö Ang#x0342; ◽  
...  
Keyword(s):  
Single Dose ◽  
Ureaplasma Urealyticum ◽  
Microbiological Diagnosis ◽  
Dose Administration ◽  
Complete Eradication ◽  
Gonococcal Urethritis ◽  
Dose Oral ◽  
Male Patients ◽  
Oral Azithromycin

In an uncontrolled study, the efficacy of azithromycin in the treatment of non-gonococcal urethritis was assessed in 41 male patients aged between 20 and 40 years with a mean age of 27 ± 5 years. Clinical and microbiological diagnosis confirmed that 28 men were found positive for Chlamydia trachomatis, 10 for Ureaplasma urealyticum and three for both C. trachomatis and U. urealyticum. All patients received 1 g azithromcyin orally (four 250 mg capsules). The length of time between the treatment and following visits were 7 – 10 days and 14 – 21 days for second and third visits, respectively. Complete eradication was achieved in 27 out of 41 patients. Of the remaining 14, six were found positive for C. trachomatis and were excluded as they did not return for the follow-up visit, one patient did not achieve complete eradication, one patient infected with both C. trachomatis and U. urealyticum failed to achieve complete eradication, and six patients infected with U. urealyticum failed to be completely cured. No adverse effects were reported in any patient. Single dose administration of 1 g azithromycin appears to be an effective and well-tolerated treatment for chlamydial urethritis and an advantage in terms of patient compliance.

scholarly journals Assessment of oltipraz in schistosomiasis mansoni clinical trial

1984 ◽  
Vol 26 (3) ◽  
pp. 147-151 ◽  
Author(s):  
Naftale Katz ◽  
Roberto S. Rocha ◽  
Adelú Chaves
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Oral Dose ◽  
Single Oral Dose ◽  
Cure Rate ◽  
Schistosomiasis Mansoni ◽  
Significant Difference ◽  
Real Value ◽  
Kidney Functions ◽  
Abdominal Distress

Seventy three children (6-15 years) and 75 adults (18-47 years) with active schistosomiasis mansoni were treated with oltipraz. All cases had at least 100 eggs per gram of feces as determined by the Kato-Katz technique. Children and adults were divided in two groups receiving respectively 25 or 30 mg/kg, as a single oral dose. Clinical examination, laboratories tests (haemogram, urinalysis, hepatic and kidney functions tests, glycemia, cholesterol, triglicerides, lipoprotein — HLD and LDL) and ECG were performed before, 3 or 7 days and 1 month after treatment. Parasitological control with 3 daily coprological examinations, was done on the 1st, 3rd j 6th month after drug administration. Giddiness, somnolence, headache, nausea, vomiting and abdominal distress were the most frequent side effects. Pain in the finger tips that need further investigations also occurred. No significant alteration in complementary tests were observed, whereas eosinophilia 1 month after treatment was detected, probably indicating worm death. The cure rate in children was 81.8% and 74.2% with 25 and 30 mg/kg respectively, and in adults 75.0% and 81.2% of the patients. No statistical significant difference was observed between cure rate and side effects at different dosages employed, neither between adults nor children. In all groups the percentage of egg reduction in feces in the non cured patients was higher than 96.0%. Further investigation with this new compound is necessary to accomplish the real value of oltipraz in the schistosomiasis chemotherapy.

Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males

1993 ◽  
Vol 31 (suppl E) ◽  
pp. 177-183 ◽  
Author(s):  
J. Lauharanta ◽  
K. Saarinen ◽  
M.-T. Mustonen ◽  
H.-P. Happonen
Keyword(s):  
Single Dose ◽  
Gonococcal Urethritis ◽  
Dose Oral ◽  
Oral Azithromycin

Single Oral Dose of Ampicillin-Probenicid as Gonorrhoea Treatment: Antibiotic Levels in Urethral Exudate

1974 ◽  
Vol 2 (4) ◽  
pp. 298-301
Author(s):  
J Martins de Barros ◽  
Jairo P de Menezes ◽  
Jose Ximenes
Keyword(s):  
Side Effects ◽  
Oral Dose ◽  
Single Oral Dose ◽  
Cure Rate ◽  
Post Dose ◽  
Dose Treatment ◽  
Gonococcal Urethritis ◽  
Male Patients

Sixty male patients aged between sixteen and thirty years suffering from acute gonococcal urethritis in whom a urethral exudate had been present from one to thirty-nine days participated in this study here described. Each patient was given one single oral dose of ampicillin-probenicid and follow-up examinations were carried out before the end of the fifth day, between the eighth and twelfth days, and in many cases also between the fifteenth and twentieth days post-dose. In fifty-eight of the sixty cases urethral exudate disappeared and cultures were negative within ten to forty-eight hours after dosing; thus demonstrating a 96·7% cure rate. This form of single oral dose treatment for gonorrhoea, apart from proving extremely effective, was highly acceptable to all of the patients admitted to this study and produced no side-effects.

Single dose oral azithromycin versus seven day doxycycline in the treatment of non-gonococcal mucopurulent endocervicitis

2000 ◽  
Vol 40 (1) ◽  
pp. 44-47 ◽  
Author(s):  
Fatih şendaǧ ◽  
Coşan Terek ◽  
Güngör Tuncay ◽  
Erdinç özkinay ◽  
Melih Güven
Keyword(s):  
Single Dose ◽  
Dose Oral ◽  
Oral Azithromycin
Sign in / Sign up

Export Citation Format

Share Document